American Heart Association 2019 Late-breaking Trials – Diagnostic and Interventional Cardiology

November 19, 2019 Here is a list of the key late-breaking clinical study presentations and links to the results at the 2019 American Heart Association (AHA) annual meeting, Nov. 16-18, 2019, in Philadelphia.Find details on the AHA Scientific-Sessions.

DAPA-HF: The Dapagliflozin and Prevention of Adverse-outcomes in Heart Failure Trial: Results in Nondiabetic Patients. Presented by John J. V. McMurray, BHF Cardiovascular Reseach Centre, Glasgow, United Kingdom.

AHA's in-depth DAPA-HF page

Safety and Efficacy of Inclisiran in Patients With ASCVD and Elevated LDL Cholesterol - Results From the Phase 3 ORION-10 Trial. Presented by R. Scott Wright, Mayo Clinic, Rochester, Minn.

AHA's in-depth ORION-10 page

The COLchicine Cardiovascular Outcomes Trial (COLCOT). Presented by Jean-Claude Tardif | Montreal Heart Institute, Montreal, QC, Canada

AHA's in-depth COLCOT page.

https://www.acc.org/latest-in-cardiology/articles/2019/11/14/13/36/sat-1045am-betonmace-effect-of-bet-protein-inhibition-apabetalone-aha-2019 Presented by Kausik K. Ray, Imperial College of London, London, United Kingdom.

AHA's in-depth BETonMACE page.

ISCHEMIA - International Study of Comparative Health Effectiveness With Medical and Invasive Approaches: Primary Report of Clinical Outcomes. Presented by Judith S. Hochman, NYU School of Medicine, New York, on behalf of the ISCHEMIA Research Group.

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches- Chronic Kidney Disease (ISCHEMIA-CKD): Primary Results of Clinical Outcomes. Presented by Sripal Bangalore, New York University School of Medicine, New York, N.Y. on behalf of the ISCHEMIA-CKD Research Group

AHA's in-depth ISCHEMIA-CKD page

Global Comparison of a Rivaroxaban-Based Antithrombotic Strategy versus an Antiplatelet-Based Strategy After Transcathether Aortic Valve Replacement (TAVR) to Optimize Clinical Outcomes (GALILEO) Trial: Primary Results. Presented by George Dangas, M.D., Mount Sinai Hospital, New York.

AHA's in-depth GALILEO page.

Randomized Clinical Trial Comparing a Rivaroxaban-Based Strategy With an Antiplatelet-Based Strategy for the Prevention of Subclinical Leaflet Thrombosis in Transcatheter Aortic Valves (GALILEO-4D). Presented by Ole De Backer, Rigshospitalet University Hospital, Copenhagen, Denmark. Balloon-Expandable versus Self-Expandable TAVR on Paravalvular Regurgitation and 2-Year Mortality: A Propensity-Matched Comparison From the FRANCE-TAVI Registry. Presented by Eric Van Belle, Institute Coeur Poumon - CHU Lille, Lille, France

RECOVERY: Early Surgery versus Conventional Management for Asymptomatic Severe Aortic Stenosis. Presented by Duk-Hyun Kang, Asan Medical Center, Seoul, Republic of Korea.

TWILIGHT-ACS: Ticagrelor with Aspirin or Alone in High-Risk Bleeding Patients after Coronary Intervention for Acute Coronary Syndrome. Presented by Usman Baber, Icahn School of Medicine at Mount Sinai, New York.

Colchicine in Percutaneous Coronary Intervention. Presented by Binita Shah, VA New York Harbor Healthcare System, NYU School of Medicine.

OCT COMPLETE: Non-culprit Lesion Plaque Morphology in Patients with ST-segment Elevation Myocardial Infarction: Substudy from the Complete Trial using Optical Coherence Tomography (OCT). Presented by Natalia Pinilla Echeverri, McMaster University, Hamilton, Canada.

COACT: One Year Outcomes of Coronary Angiography After Cardiac Arrest. Presented by Jorrit Lemkes, Amsterdam University Medical Center, Amsterdam, Netherlands.

Mortality and Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Percutaneous Coronary Intervention With Impella vs Intra-Aortic Balloon Pump (IABP). Presented by Sanket Dhruva, M.D., UCSF School of Medicine, San Francisco.

Comparative Effectiveness and Costs of Impella versus Intra-aortic Balloon Pump (IABP) in the United States. Presented by Amit P. Amin, M.D., Washington University School of Medicine, Saint Louis, Mo.

FUEL - Results From the Pediatric Heart Networks Fontan Udenafil Exercise Longitudinal Trial. Presented by David J. Goldberg, Children's Hospital of Philadelphia, Philadelphia.

Effect of Treatment According to Age in the Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure Trial (DAPA-HF). Presented by Felipe Martinez, Insto Damic, Cordoba, Argentina.

Effect of treatment measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) in the Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure. Presented by John J. McMurray, BHF Cardiovascular Research Centre, Glasgow, United Kingdom.

PARAGON-HF: LBCT: Effects of Sacubitril/Valsartan in Women Compared to Men With Heart Failure and Preserved Ejection Fraction. Presented by John J. McMurray, University of Glasgow, Glasgow, United Kingdom.

PARAGON-HF Secondary Analysis: Effect of Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Presented by Scott D. Solomon, Brigham and Women's Hospital, Boston.

EVAPORATE: Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients With Elevated Triglycerides (200-499 mg/dl) on Statin Therapy. Presented by Matthew J. Budoff, M.D., Lundquist Institute and UCLA School of Medicine, Torrance, Calif.

Safety and Efficacy of Inclisiran in Patients With Heterozygous Familial Hypercholesterolemia - Results From the Phase 3 ORION-9 Trial. Presented by Frederick J. Raal, Johannesburg Hospital, Johannesburg, South Africa.

AHA's in-depth ORION-9 page.

RNA Interference Targeting Apolipoprotein C-III Results in Deep and Prolonged Reductions in Plasma Triglycerides. Presented by Christie M. Ballantyne, Baylor College of Medicine, Houston, Texas.

RNA Interference Targeting Hepatic Angiopoietin-Like Protein 3 Results in Prolonged Reductions in Plasma Triglycerides and LDL-C in Human Subjects. Presented by Gerald F. Watts, University of Western Australia, Royal Perth Hospital, Perth, Australia.

Benefit of a Target LDL Cholesterol Less Than 70 mg/dl After an Ischemic Stroke of Atherosclerotic Origin, the Treat Stroke to Target Trial Results. Presented by Pierre Amarenco, Paris University, Paris, France.

E-Cigarettes May Be More Harmful to Heart Health Than Tobacco

Many Adults with Heart Failure at Higher Risk of Death after Surgery

New Algorithms in Medtronic Micra Pacemaker May Improve Synchrony and Cardiac Function in AV Block

ASCVD Patients Face Barriers Reaching Guideline-Recommended Cholesterol Goals

American Heart Association 2018 Late-breaking Trials

ACC 2019 Late-breaking Presentations

Late-breaking Interventional Cardiology Presentations at SCAI 2019

American Heart Association 2018 Late-breaking Trials

TCT 2019 Late-breaking Presentations

VIVA 2019 Late-breaking Clinical Trials

Follow this link:

American Heart Association 2019 Late-breaking Trials - Diagnostic and Interventional Cardiology